Marshall A. Schorin

The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia

Steven E. Lipshultz, Nader Rifai, Virginia Dalton et al. · New England Journal of Medicine · 2004 · 620 citations

Medicine, Pharmacology, Pharmacotherapy +17

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

Steven E. Lipshultz, Rebecca E. Scully, Stuart R. Lipsitz et al. · The Lancet Oncology · 2010 · 447 citations

Medicine, Pediatrics, Pharmacology +16

Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia

Albert Moghrabi, Donna E. Levy, Barbara L. Asselin et al. · Blood · 2006 · 405 citations · Full text

Medicine, Oncology, Pediatrics +8

Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations With Long-Term Echocardiographic Outcomes

Steven E. Lipshultz, Tracie L. Miller, Rebecca E. Scully et al. · Journal of Clinical Oncology · 2012 · 324 citations · Full text

Medicine, Pediatrics, Pharmacology +17

Postinduction Dexamethasone and Individualized Dosing of <i>Escherichia Coli</i> L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01

Lynda M. Vrooman, Kristen E. Stevenson, Jeffrey G. Supko et al. · Journal of Clinical Oncology · 2013 · 315 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17